Premium Company Profile: Depomed

Depomed is a specialty pharmaceutical company engaged in the development and commercialization of products that are based on its oral drug delivery technologies. Depomed's business strategy is using its proprietary drug delivery technology AcuForm to potential product candidates of its own and other pharmaceutical companies.

Report Highlights
Depomed's marketed products Glumetza and Proquin are related to indications Type II Diabetes and urinary tract infections respectively. Depomed derives its revenues from sales of its products, royalties and license and collaboration fees. Depomed's current operating plan focuses on maximizing the revenues through license and collaboration arrangements with other pharma and biotech companies and commercializing of its existing product portfolio. The company's total revenues increased at a CAGR of 54.8% during 2002-2006, from $1.7 million to $9.6 million. The company's biggest contributor to revenue growth during 2002-2006 was revenues from license and collaboration growing at a CAGR of 22.3% during 2002-2006.
[Studien Infos ausblenden]

Overview 1
Catalyst 1
Summary 1
Company Structure 6
Company Overview and Key Facts 6
Business Description 7
History 8
Company Financials 11
Stock Market Performance 11
P&L 12
Balance Sheet 16
Cash Flow 16
Business Segment Performance 17
Products & Services 19
Marketed Products 19
Pipeline Products 20
Historical Product Sales 23
AC Forecast Product Sales 24
Competitors and Strategic Business Relationships 26
Key Competitors 26
Key Suppliers 27
Key Clients 27
Shareholding Structure 28
Strategy 29
Company View 29
Corporate Strategy 30
SWOT Analysis 32
Overview 32
Strengths 33
Weaknesses 34
Opportunities 35
Threats 37
Value Chain Analysis 39
Overview 39
Discovery and Product Development 39
Manufacturing 40
Sales 40
Scorecard 41
Overview 41
Scorecard Analysis 42
Key Employees 43
List of Key Employees 43
Key Employee Biographies 44
Financial and Operational Overview 48
Financial and Operational Overview 48
APPENDIX 51
Ask the analyst 51
Datamonitor consulting 51
Disclaimer 51
[Inhaltsverzeichnis ausblenden]

Table 1: Depomed - Key Facts 6
Table 2: Depomed - Year-End Share Price and Market Capitalization, 2002-2006 ($) 11
Table 3: Depomed - Key Events Impacting Share Price Performance 12
Table 4: Depomed - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn) 13
Table 5: Depomed - Operating Cost Ratio Analysis, 2002-2006 (% of total revenues) 15
Table 6: Depomed - Balance Sheet, 2002-2006 ($ Mn) 16
Table 7: Depomed - Cash Flow, 2002-2006 ($ Mn) 16
Table 8: Depomed - Revenue Breakdown by Division, 2002-2006 ($ Mn) 17
Table 9: Depomed - Marketed Products 19
Table 10: Depomed - In-house Pipeline Products 20
Table 11: Depomed - Collaboration Products 21
Table 12: Depomed - Historical Sales, 2002-2006 ($ Mn) 23
Table 13: Depomed - Forecast Sales, 2006-2010 ($ Mn) 24
Table 14: Depomed – Key Competitors 26
Table 15: Depomed - Key Shareholders 28
Table 16: Depomed - SWOT Analysis Summary 32
Table 17: Depomed – Value Chain Analysis 39
Table 18: Depomed - Scorecard 41
Table 19: Depomed - Key Employees 43
Table 20: Depomed - Financial and Operational Overview 49
Figure 1: Depomed - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn) 14

Figure 2: Depomed - Key Strategic Revenues, 2002-2006 ($ Mn) 18

Figure 3: Depomed - Key Strategic Revenues, 2006-2010 ($ Mn) 25
[Tabellenverzeichnis ausblenden]